Selected article for: "acute respiratory syndrome and additional role"
Author: Eric W. Stawiski; Devan Diwanji; Kushal Suryamohan; Ravi Gupta; Frederic A. Fellouse; J. Fah Sathirapongsasuti; Jiang Liu; Ying-Ping Jiang; Aakrosh Ratan; Monika Mis; Devi Santhosh; Sneha Somasekar; Sangeetha Mohan; Sameer Phalke; Boney Kuriakose; Aju Antony; Jagath R. Junutula; Stephan C. Schuster; Natalia Jura; Somasekar Seshagiri
Title: Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility
  • Document date: 2020_4_10
    • ID: jfdshwfh_32
    Snippet: The expression levels of ACE2 and its variants in appropriate host tissue may modulate the deleterious effect of the virus. To further understand the importance of the ACE2 variants in susceptibility, it will be important to correlate clinical outcomes with ACE2 genotypes at population scale. The extremes in COVID-19 clinical symptoms reported ranging from asymptomatic infected adult individuals to those that show acute respiratory syndrome leadi.....
    Document: The expression levels of ACE2 and its variants in appropriate host tissue may modulate the deleterious effect of the virus. To further understand the importance of the ACE2 variants in susceptibility, it will be important to correlate clinical outcomes with ACE2 genotypes at population scale. The extremes in COVID-19 clinical symptoms reported ranging from asymptomatic infected adult individuals to those that show acute respiratory syndrome leading to death (Cao et al., 2020b; Cascella et al., 2020; Yuen et al., 2020) , suggest a role for additional factors, including the role of innate and adaptive immunity, besides ACE2 variants in modifying disease outcomes.

    Search related documents:
    Co phrase search for related documents
    • acute death lead respiratory syndrome and death lead respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive innate immunity and clinical outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adaptive innate immunity and clinical outcome correlate: 1
    • adaptive innate immunity and death lead: 1, 2
    • adaptive innate immunity and disease outcome: 1, 2, 3
    • adaptive innate immunity and expression level: 1, 2, 3
    • adaptive innate immunity and host tissue: 1, 2, 3, 4
    • adaptive innate immunity role and clinical outcome: 1
    • additional factor and clinical outcome: 1, 2
    • additional factor and clinical symptom: 1
    • additional factor and disease outcome: 1
    • additional factor and host tissue: 1
    • appropriate host tissue and host tissue: 1, 2
    • clinical outcome and death lead: 1, 2, 3, 4, 5, 6, 7
    • clinical outcome and deleterious effect: 1, 2, 3, 4, 5, 6
    • clinical outcome and disease outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical outcome and expression level: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical outcome and host tissue: 1, 2, 3, 4, 5
    • clinical outcome correlate and disease outcome: 1, 2